Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.
Neuroendocrine Tumors, NET
DRUG: Lu-177 DOTA-TATE
Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE, Data (Radioisotope and CT/MRI images, blood assays and Quality of Life Questionnaires, pre and post treatment) will be collected to determine tumor response of subjects with NET after treatment with Lu-177 DOTA-TATE., Retrospective data January 2010 - April 30, 2014
Safety and other relevant information on subjects treated with Lu-177 DOTA-TATE, Safety data will include blood counts and chemistry, GFR and adverse events, pre and post treatment. Other data includes patient demographics., Retrospective data January 2010 - April 30, 2014
Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.